Market Cap | 658.62M | P/E | - | EPS this Y | 1.40% | Ern Qtrly Grth | - |
Income | -252.45M | Forward P/E | -2.74 | EPS next Y | -8.40% | 50D Avg Chg | -15.00% |
Sales | 10.6M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -41.00% |
Dividend | N/A | Price/Book | 1.18 | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | 1.70 | Quick Ratio | 15.61 | Shares Outstanding | 118.22M | 52W Low Chg | 5.00% |
Insider Own | 4.88% | ROA | -18.20% | Shares Float | 90.74M | Beta | 0.89 |
Inst Own | 97.18% | ROE | -28.36% | Shares Shorted/Prior | 11.98M/12.92M | Price | 9.30 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,032,227 | Target Price | 66.09 |
Oper. Margin | -4,040.39% | Earnings Date | Nov 6 | Volume | 592,968 | Change | -2.31% |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Goldman Sachs | Buy | Sep 24, 24 |
Cantor Fitzgerald | Overweight | Sep 18, 24 |
Cantor Fitzgerald | Overweight | Sep 16, 24 |
Cantor Fitzgerald | Overweight | Sep 9, 24 |
Barclays | Overweight | Aug 28, 24 |
Evercore ISI Group | Outperform | Aug 26, 24 |
Needham | Buy | Aug 13, 24 |
Evercore ISI Group | Outperform | Aug 12, 24 |
Chardan Capital | Buy | Aug 9, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LEVIN ARTHUR A | Director Director | Jan 22 | Sell | 10.13 | 1,859 | 18,832 | 17,471 | 01/23/24 |
Boyce Sarah | President and CEO President and CEO | Jan 20 | Sell | 10.13 | 5,092 | 51,582 | 44,008 | 01/23/24 |
Flanagan W. Michael | CSTO CSTO | Jan 20 | Sell | 10.13 | 4,129 | 41,827 | 35,871 | 01/23/24 |
McCarthy Teresa | Chief Human Resource.. Chief Human Resources Officer | Jan 20 | Sell | 10.13 | 2,065 | 20,918 | 17,035 | 01/23/24 |
MacLean Michael F | Chief Financial Offi.. Chief Financial Officer | Jan 20 | Sell | 10.13 | 1,616 | 16,370 | 16,884 | 01/23/24 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Feb 14 | Sell | 23.93 | 10,000 | 239,300 | 19,330 | 02/15/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Feb 14 | Option | 1.24 | 10,000 | 12,400 | 29,330 | 02/15/23 |
Boyce Sarah | President and CEO President and CEO | Feb 01 | Sell | 24.3 | 50,000 | 1,215,000 | 53,352 | 02/03/23 |
Boyce Sarah | President and CEO President and CEO | Feb 01 | Option | 1.24 | 50,000 | 62,000 | 56,573 | 02/03/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jan 12 | Sell | 22 | 10,000 | 220,000 | 1,330 | 01/17/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jan 12 | Option | 1.24 | 10,000 | 12,400 | 11,330 | 01/17/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Dec 29 | Sell | 22.01 | 40,000 | 880,400 | 1,330 | 01/03/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Dec 29 | Option | 1.24 | 40,000 | 49,600 | 41,330 | 01/03/23 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Aug 12 | Option | 0.89 | 80,000 | 71,200 | 4,829 | 08/31/22 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Aug 12 | Sell | 22.07 | 80,000 | 1,765,600 | 1,330 | 08/31/22 |
Boyce Sarah | President and CEO President and CEO | Aug 24 | Option | 1.24 | 49,900 | 61,876 | 14,855 | 08/26/22 |
Boyce Sarah | President and CEO President and CEO | Aug 24 | Sell | 22.93 | 49,900 | 1,144,207 | 08/26/22 | |
Boyce Sarah | President and CEO President and CEO | Aug 15 | Option | 1.24 | 100 | 124 | 100 | 08/17/22 |
Boyce Sarah | President and CEO President and CEO | Aug 15 | Sell | 22.47 | 100 | 2,247 | 08/17/22 | |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jun 28 | Option | 1 | 20,200 | 20,200 | 21,430 | 06/28/21 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jun 22 | Option | 1.24 | 200 | 248 | 1,530 | 06/22/21 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jun 22 | Sell | 27.75 | 200 | 5,550 | 1,330 | 06/22/21 |
LEVIN ARTHUR A | Chief Scientific Off.. Chief Scientific Officer | Jun 16 | Sell | 25.97 | 37,022 | 961,461 | 06/16/21 |